Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia-Lymphoma, Adult T-Cell 1Immunoblastic Lymphadenopathy 1Epstein-Barr Virus Infections 1

Interventions

Rituximab 10Valganciclovir 6Etoposide 4Doxorubicin 4Valacyclovir 3Gemcitabine 3Dexamethasone 3Cyclophosphamide 3Cisplatin 3spartalizumab 2pembrolizumab 2pegaspargase 2Zidovudine 2Vincristine 2Radiotherapy, Intensity-Modulated 2Prednisone 2Methylprednisolone 2Methotrexate 2Matrix-M 2Leucovorin 2Lenalidomide 2Cell Count 2Carboplatin 2Blood Specimen Collection 2Acyclovir 2valomaciclovir 1toripalimab 1threonic acid 1ruxolitinib 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epstein-Barr Virus Infections × brincidofovir × Clear all
NCT06761677 2026-02-05

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

SymBio Pharmaceuticals

Phase 1/2 Suspended
43 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Epstein-Barr Virus Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡